Therefore, the loss of SLAMF1 expression (SLAMF1low) could indicate an aggressive form of CLL and hence could help in improving patient management as predictive factor of overall survival (OS). This evidence concerns the gene SLAMF1 and B-cell chronic lymphocytic leukemia.